Adriamycin in advanced bronchogenic carcinoma

Abstract

Adriamycin, a new cytotoxic antibiotic with antitumor activity in a variety of neoplasms, was given to 31 patients with advanced bronchogenic carcinoma. The doses used were 30 and 35 mg/m2 of body surface area daily for 3 days repeated at 3‐ or 4‐week intervals. Objective regression (<50%) was seen in 4 of 20 patients receiving 30 mg/m2 and 5 of 11 patients receiving 35 mg/m2. Regressions according to histologic cell type were seen in 5 of 17 adenocarcinomas, 3 of 6 small cell carcinomas, 1 of 6 large cell anaplastic carcinomas, and 0 of 2 squamous cell carcinomas. Those patients who attained tumor regression survived longer than those who had progression. Toxic manifestations of Adriamycin administration were myelosuppression, stomatitis, cardiomyopathy, and nausea and vomiting. Adriamycin at doses below the cumulative cardiotoxic threshold appears to be of clinical value in advanced bronchogenic carcinoma.

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

“…The overall response rate in the phase I-II study was 25.0% (95% CI, 10.7% to 44.9%): 7 PRs in 28 previously untreated patients. These data suggest that amrubicin may be one of the promising agents in the treatment of NSCLC, because it showed reproducible response rates of more than 20% in two clinical studies as described above, while doxorubicin showed only marginal activity against NSCLC [12].…”

“…Amrubicin is a totally synthetic 9-aminoanthracycline, and its chemical structure is similar to those of doxorubicin and epirubicin. Doxorubicin is now widely used as an important agent in the treatment of many tumor types such as malignant lymphoma, breast cancer, and soft tissue sarcoma; however, its single-agent activity for NSCLC has been reported to be only marginal, because its response rate was less than 15% [12,19]. Epirubicin is an analog of doxorubicin.…”

Current Status of Epirubicin (Farmorubicin) in the Treatment of Solid Tumours

“…In these three studies, a total of 210 patients had an overall response rate of 6% (159)(160)(161). However, a phase I1 trial with doxorubicin at higher doses (90-105 mg/mZ every 3-4 weeks) induced 24% responses among 25 patients (162). Based on these results, epirubicin and doxorubicin appear equally active when given in equitoxic doses.…”

Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study

“…Overall response rate in the phase I-II study was 25.0% (95% CI, 10.7 to 44.9%), with seven PRs in 28 previously untreated patients. These reproducible response rates of more than 20% in two clinical studies suggest that amrubicin may be a promising agent in the treatment of NSCLC, in contrast to doxorubicin which shows only marginal activity against NSCLC [13].…”